In breast cancer cells, β‐catenin binds to p65‐p50 complex and inhibits its nuclear translocation.17 β‐TrCP1 simultaneously activates NF‐κB and inhibits WNT pathways in the vascular smooth muscle cells.18 IKKα inhibitor blocks WNT downstream gene CCND1 expression in mouse embryo fibroblasts.19 These findings imply that the crosstalk of the two pathways should be the key to IDD target treatment. The gene discussed is NFKB1; the disease is breast cancer.